Citations

Clear

1446 citation(s) found for "Howard, F".

Abstract 4935: Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer
Sodipo, Michelle O. , Siefkas, Anna , Sauer, Christopher M. , Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Khoo, Vincent , Ogo, Chidiebere, McKay, Rana R. , Fischer, Stefanie , Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille , Anderson, Simon , Cannon, Laurel, Chan-Cuzydlo, Alyssa, Grant, Marie, Gerke, Travis , George, Daniel J. , Mucci, Lorelei A. , Anderson, Simon G , Hotte, Sebastien J , Guard, Hannah E. , McGrath, Colleen B. , Howard, Lauren E. , Stopsack, Konrad H. , Dreicer, Robert , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Kolinsky, Michael Paul , Mateo, Joaquı́n , Cheng, Heather H. , Szmulewitz, Russell Z , Whang, Young E. , Sharma, Anand , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Badal, Simone , GREAVES, NATALIE S. , Autio, Karen A. , Cannon, Laurel, McManus, Hannah D. , Kantoff, Philip W.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 4935-4935

10.1158/1538-7445.am2025-4935 Get It

Abstract Introduction: Most people who die from prostate cancer are older than 75 years. However, prostate cancer diagnosed at younger ages is often more aggressive. While epidemiologic studies have examined the association between age and survival in patients with prostate cancer overall, the clinical drivers of this relationship in patients with advanced disease remain unclear. We leveraged the International Registry of Men with Advanced Prostate Cancer (IRONMAN, NCT03151629) to (1) quantify the association between age and overall survival and (2) explore whether this association is explained by treatments. Methods: We included 3, 734 patients enrolled from 15 countries with new diagnoses of metastatic hormone sensitive (mHSPC, N=2, 642) or castration resistant prostate cancer (CRPC, N=1, 092). Age at enrollment was categorized as <55, 55-59, 60-64 (reference), 65-69, 70-74, 75-79, 80-84, 85+ years. We computed age-specific death rates (95% confidence intervals [CIs]) by disease state (mHSPC, CRPC) at enrollment. To explore whether this relationship was explained by treatment, we fitted disease state-stratified Cox models and sequentially adjusted for (1) de novo metastatic status and country, and (2) baseline treatment (androgen deprivation therapy [ADT] alone, ADT + androgen receptor pathway inhibitors [ARPI], ADT + chemotherapy, ADT + ARPI + chemotherapy, other). Results: Over 5.5 years of follow-up (median: 3.2 years, IQR: 1.7, 4.8), 995 patients died from any cause. Younger patients were more likely to have de novo metastatic disease. Among those with mHSPC at enrollment, the age-specific death rates per 1, 000 person-years followed a J-shaped pattern: 80 (95% CI: 54, 117) in patients under 55 years, 58 (46, 74) in patients aged 60-64, 102 (78, 133) in patients aged 80-84, and 172 (125, 236) in patients aged 85 and older. The death rates among those with CRPC followed a similar pattern, albeit rates were higher in magnitude: 212 (95% CI: 140, 323) in patients under 55 years, 153 (115, 202) in patients aged 60-64, 200 (155, 258) in patients aged 80-84, and 204 (142, 291) in patients aged 85 and older. After adjusting for disease state, country, and the timing of diagnosis of metastases, death rates were substantially higher for ages 75-79 (HR 1.4; 95% CI 1.1, 1.7), 80-84 years (HR 1.6; 95% CI 1.2, 2.1), and 85 years and older (HR 2.0; 95% CI: 1.5, 2.7) compared to ages 60-64 years. Patients aged under 55 years had 1.4-fold higher death rates (95% CI: 1.0, 1.9) compared to those 60-64 years. After additionally adjusting for baseline treatment, overall survival remained worse for the older patients and the youngest age group with hazard ratios remaining meaningfully unchanged. Conclusion: Age at enrollment is associated with overall survival in people with advanced prostate cancer enrolled in IRONMAN in a J-shaped pattern. This relationship is not explained by differences in baseline treatment. Citation Format: Hannah E. Guard, Michelle O. Sodipo, Colleen B. McGrath, Anna Siefkas, Lauren E. Howard, Konrad H. Stopsack, Christopher M. Sauer, Robert Dreicer, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim N. Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, Michael Kolinsky, Vincent Khoo, Joaquin Mateo, Chidiebere N. Ogo, Rana R. McKay, Stefanie Fischer, Heather H. Cheng, Russell Szmulewitz, Young E. Whang, Anand Sharma, Frédéric Pouliot, Simon Crabb, Monica S. Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi T. Odedina, Simon Anderson, Simone Badal, Natalie Greaves, Karen A. Autio, Laurel Cannon, Alyssa Chan-Cuzydlo, Marie Grant, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel J. George, Lorelei A. Mucci, IRONMAN investigator team. Disentangling the association between age and overall survival in an international cohort of patients with advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4935.
Abstract 3630: First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors
Sodipo, Michelle O. , Siefkas, Anna , Drecier, Robert, Dogo, Hassan, Waihenya, Charles, Hotte, Sebastién J. , Cathomas, Richard , Enting, Deborah , Heath, Elisabeth I. , McKay, Rana R. , Fischer, Stefanie, Chatwal, Monica , McDermott, Raymond, Davis, Ian D. , Ragin, Camille, Anderson, Simon , Harrison, Sharon , Cannon, Laurel, Grant, Marie, Chan-Cuzydlo, Alyssa, Gerke, Travis , George, Daniel, Haneuse, Sebastien , Mucci, Lorelei A. , Registry, on behalf of the IRONMAN, Anderson, Simon G , Hotte, Sebastien J , Morgans, Alicia K. , Warner, Erica T. , Rencsok, Emily M. , Howard, Lauren E. , McGrath, Colleen B. , Stopsack, Konrad H. , Sauer, Christopher Martin , Esteban, Emilio , Popoola, Ademola , Bjartell, Anders , N., Kim , Tagawa, Scott T. , Ong, Michael M. , Lorente, David , Cheng, Heather H. , Whang, Young E. , Pouliot, Frédéric , Crabb, Simon J. , Climent, Miguel A., McDermott, Raymond, Ragin, Camille , GREAVES, NATALIE S. , Badal, Simone , Autio, Karen A. , McManus, Hannah D. , Kantoff, Philip W. , Registry, on behalf of the IRONMAN

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3630-3630

10.1158/1538-7445.am2025-3630 Get It

Abstract Introduction: The standard of care for metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with the expanded approval of androgen receptor pathway inhibitors (ARPIs) alongside androgen deprivation therapy (ADT). ADT alone has been shown to affect cognitive function. However, the cognitive impact of distinct treatment combinations remains unclear. We investigated the association between first-line systemic treatments and the trajectory of subjective cognitive function among mHSPC survivors in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: This analysis included 2435 newly diagnosed mHSPC patients enrolled across 15 countries between July 2017 and August 2024. Treatments were reported by site personnel and physicians. For this analysis, we focused on first-line systemic treatment and classified treatment groups at enrollment as ADT monotherapy (referent), ADT + ARPIs, or ADT + chemotherapy. Subjective cognitive function was assessed via the EORTC QLQ-C30 Cognitive Function subscale, with patient-reported scores (range 0-100) collected at enrollment and every 3 months for up to 5 years; higher scores reflect better cognitive function. Associations were estimated using linear mixed effects models with clustering by study site and country to examine differences at enrollment and across trajectories of subjective cognitive function by first-line treatment, adjusting for demographic and clinical factors. Results: Median age at enrollment was 70 years, with a median follow-up of 1.7 years. 724 (30%) participants were treated with ADT monotherapy, 1317 (54%) with ADT + ARPIs, and 394 (16%) with ADT + chemotherapy. Mean cognitive function scores at enrollment were 85.4 (Standard Deviation [SD] 19.5) for participants treated with ADT monotherapy, 86.7 (SD 17.3) for ADT + ARPIs, and 86.7 (SD 18.0) for ADT + chemotherapy. Cognitive function scores decreased by -0.60 points (95% Confidence Interval [CI] -0.72, -0.48) per year among those treated with ADT monotherapy, with similar rates observed for those treated with ADT + chemotherapy. Participants treated with ADT + ARPIs had a slower decline in cognitive function, with scores decreasing by -0.36 points (95% CI -0.60, -0.08) per year. Conclusion: In this international cohort of mHSPC survivors, subjective cognitive function scores were generally high at enrollment but declined over time. There was no evidence of worse cognitive function in those treated with ADT + ARPIs nor ADT + chemotherapy over time compared to ADT monotherapy. Cognitive functioning is a key component of survivorship, and defining cognitive trajectories associated with first-line treatment can inform supportive interventions, patient treatment decision-making, and clinical guidelines. Citation Format: Michelle O. Sodipo, Alicia K. Morgans, Erica T. Warner, Emily M. Rencsok, Lauren E. Howard, Colleen B. McGrath, Anna Siefkas, Konrad H. Stopsack, Christopher Sauer, Robert Drecier, Emilio Esteban, Hassan M. Dogo, Ademola Popoola, Charles Waihenya, Anders Bjartell, Kim Chi, Sebastien Hotte, Richard Cathomas, Deborah Enting, Scott Tagawa, Michael Ong, David Lorente, Elisabeth Heath, Rana McKay, Stefanie Fischer, Heather H. Cheng, Young E. Whang, Frederic Pouliot, Simon Crabb, Monica Chatwal, Miguel A. Climent, Raymond McDermott, Ian D. Davis, Camille Ragin, Folakemi Odedina, Natalie Greaves, Simone Badal, Simon Anderson, Sharon Harrison, Karen Autio, Laurel Cannon, Marie Grant, Alyssa Chan-Cuzydlo, Travis Gerke, Hannah D. McManus, Philip W. Kantoff, Daniel George, Sebastien Haneuse, Lorelei A. Mucci, on behalf of the IRONMAN Registry. First-line therapies and subjective cognitive function trajectories among international metastatic hormone-sensitive prostate cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3630.
Abstract 5919: Performance of the Oncuria-detect bladder cancer test for evaluating patients presenting with hematuria: results from a real-world clinical setting
Zhang, Zhen , Tikhonenkov, Sergei, Goodison, Steve , Sakatani, Toru , Murakami, Kaoru , Kim, Howard , Lee, Riko, Tanaka, Sunao , Rosser, Charles J. , Pagano, Ian , Calvez‐Kelm, Florence Le , Kobayashi, Takashi , Furuya, Hideki

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 5919-5919

10.1158/1538-7445.am2025-5919 Get It

Abstract Background and Objective: Bladder cancer is the 9th most diagnosed cancer worldwide with high incidences reported in Europe and the United States. Here, we evaluated the real-world performance of a commercially available multiplex immunoassay Oncuria-Detect that detects bladder cancer by simultaneously measuring a panel of 10 biomarker proteins in naturally voided urine samples. Methods: We tested prospectively collected urine samples from a real-world cohort of 1, 002 patients presenting to five USA centers, one European center and one Japanese center with hematuria. Assay results were collated with patient clinical data and a cancer diagnosis was defined by biopsy and pathology. The prevalence of bladder cancer in the cohort was 15.9%. Results: In a training set (n=684), the Oncuria-Detect assay correctly identified bladder cancer in 94/109 cases, representing a sensitivity of 91.8%, specificity of 71.6% (AUC 0.885; 95% CI 0.843 - 0.927) and with improved performance for high-grade bladder cancer and muscle-invasive bladder cancer (sensitivity 93.6% and 92.1%, respectively). In a test cohort of n =339 the AUC for detecting bladder cancer was 0.850 (95% CI 0.779-0.920). Conclusions and Implications: The multiplex Oncuria-Detect assay identified bladder cancer with high sensitivity and NPV, for low-grade and high-grade tumors alike. Oncuria-Detect’s high NPV could effectively rule out 66% of patients from requiring subsequent cystoscopy. Citation Format: Ian Pagano, Zhen Zhang, Sergei Tikhonenkov, Florence Le Calvez-Kelm, Steve Goodison, Toru Sakatani, Kaoru Murakami, Takashi Kobayashi, Howard Kim, Riko Lee, Sunao Tanaka, Charles J. Rosser, Hideki Furuya. Performance of the Oncuria-detect bladder cancer test for evaluating patients presenting with hematuria: results from a real-world clinical setting [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5919.
Abstract P1063: Association of Demographic and Clinical Factors with SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Wu, Christina , Sun, Yifei , Cushman, Mary , Boyle, Rebekah, Styer, Linda M. , Bell, Taison D., Anderson, Michaela R. , Bowler, Russell, Rock, Jean M., Bievenue, Rachel, Kandula, Namratha R. , Morganroth, Sally E, Coresh, Joe, Elkind, Mitchell S.V. , Ortega, Victor E. , Woodruff, Prescott G. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Demmer, Ryan T. , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schreiner, Pamela J. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Pirzada, Amber , Doyle, Margaret F. , Regan, Elizabeth Anne , Make, Barry J. , Kanaya, Alka M , Isasi, Carmen R. , Raffield, Laura M. , Howard, Virginia J. , Cole, Shelley A. , Henderson, Joel , Mantis, Nicholas J

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1063 Get It

Background: Despite the availability of effective vaccines and a recent decrease in annual deaths, coronavirus disease-2019 (COVID-19) remains a leading cause of death. Serological studies of anti-nucleocapsid (N) antibody response to infection provide insights into host immunobiology of adaptive immune response, which holds promise for identifying high-risk individuals for adverse acute and chronic COVID-19 outcomes. Hypothesis: Among participants previously infected with SARS-CoV-2, traditional vascular disease risk factors are associated with higher anti-N antibodies while vaccination is associated with lower anti-N antibodies. Methods: Among previously infected participants, anti-N antibodies were measured from dried blood spots collected between February 2021-February 2023 among 1,419 Collaborative Cohort of Cohorts for COVID-19 Research (C4R) participants with prior SARS-CoV-2 infection. We measured anti-N IgG antibodies reported as median fluorescence intensity (MFI) units; reactivity (i.e., seropositivity) was defined based on MFI above a validated threshold. Vascular disease risk factors were assessed via pre-pandemic in-person examination, questionnaires, and medical record review. Multivariable generalized linear models regressed anti-N reactivity (modified Poisson) or LN transformed MFI (linear). Results: Among 1,419 participants with prior infection, mean age (standard deviation) was 65.8(12.1) years, 61% were women, and 42.8% were self-reported from a race/ethnicity minority group. Participant reactivity to nucleocapsid peaked at 69% by 4 months post-infection and waned to only 44% ≥12 months after infection. After multivariable adjustment, higher anti-N antibody response was associated with older age, Hispanic (vs. White) or American Indian (vs. White) race/ethnicity, lower income and education, former smoking, and higher anti-spike antibody levels. Asian race (vs. White) and vaccination ( even after infection ) were associated with lower nucleocapsid reactivity; common cardiometabolic co-morbidities were not associated with anti-N reactivity or levels (Figures 1 and 2). Conclusions: Among participants previously infected with SARS-CoV-2, select sociodemographic and behavioral risk factors were associated with higher anti-N antibody levels while vaccination was associated with lower anti-N antibody levels. The observation that vaccination, even after infection, is related to lower anti-N antibody levels merits further investigation.
External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy
Stassen, Robert C , Maas, Carolien C. H. M. , Leong, Stanley P. L. , Kashani–Sabet, Mohammed , White, Richard L. , Pockaj, Barbara A. , Schneebaum, Schlomo , Vetto, John T. , Avisar, Eli , Howard, John H. , O’Donoghue, Cristina, Akkooi, Alexander C. J. van , Grünhagen, Dirk J. , Verhoef, Cornelis , Grünhagen, Dirk J , Olofsson Bagge, Roger , Zager, Jonathan S. , Kosiorek, Heidi , Verhoef, Cornelis , Klaveren, David V. , Bagge, Roger Olofsson

Mayo Clinic

British Journal of Surgery | April 17, 2025 | Volume: 112 | Issue: 4 | Pages: No page available

10.1093/bjs/znaf037 | PMID 40243383 Get It

Abstract Background Recently, a model to predict 5-year recurrence-free survival (RFS) and melanoma-specific survival (MSS) after sentinel lymph node biopsy (SLNB) was published. The aim of this study was to validate that model in a large independent international cohort. Methods The database of the Sentinel Lymph Node Working Group (SLNWG) was analysed for patients with malignant melanoma who underwent SLNB. Patients with clinical stage III melanoma, a history of other malignancies, or receiving concomitant systemic therapies during follow-up were excluded. The model’s predictive performance was evaluated using discrimination and calibration metrics in the eligible cohort. Decision curve analysis was performed to assess the clinical value of the model. Results The external validation cohort consisted of 6174 patients of the SLNWG from the USA, Europe, and Israel. A positive sentinel node was found in 788 patients (12.8%). The area under the time-dependent receiver operating characteristic (ROC) curve of the external validation was 0.76 (95% c.i. 0.74 to 0.77) for RFS and 0.79 (95% c.i. 0.76 to 0.81) for MSS. The model was well calibrated, as the observed 5-year survival rates aligned closely with the predicted survival rates (calibration slope of 0.98 for RFS and calibration slope of 0.99 for MSS). The model provided a net benefit versus the ‘treat all’ and ‘treat none’ strategies at the predetermined probability threshold for recurrence of 45%. Conclusion The model demonstrated good performance in a large heterogeneous independent cohort, emphasizing its robustness. Decision curve analysis revealed a clear net benefit of the model over a treat all strategy, highlighting its potential for clinical use.
Comparing Layperson Attention to Faces with Different Types of Facial Paralysis Using Eye-Tracking
Randall, Nicholas R. , Fearington, Forrest W. , Rodriguez, Gloria M., Peraza, Lazaro R. , Howard, Brittany E. , Dey, Jacob K. , Dey, Jacob K , Rodriguez, Gloria

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | April 17, 2025 | Volume: 28 | Issue: 1 | Pages: 33-41

10.1089/fpsam.2024.0324 | PMID 40242878 Get It

Background: There is a spectrum of facial paralysis patient presentations from complete flaccid facial paralysis (CFFP) to facial aberrant reinnervation syndrome (FARS). Objective: To objectively compare how laypersons direct attention to faces with different facial paralysis subtypes using eye-tracking technology. Methods: Lay observers freely gazed at standardized videos of 24 individuals’ faces as follows: 8 with CFFP, 8 with FARS, and 8 nonparalyzed Controls performing common facial expressions. Eye-tracking measured observers’ gaze and extracted data as time in milliseconds looking at facial subsites. Mixed effects regression was used for comparative analyses. Results: A total of 85 observers completed the study. For faces at rest, measurable differences in gaze patterns were noted for CFFP faces (more attention spent on nonparalyzed hemiface), whereas FARS and Control faces showed similar symmetric gaze patterns. With dynamic movement (smiling and brow-elevation), gaze patterns for both CFFP and FARS faces became altered and asymmetrical compared with Control faces. Conclusions: Faces with CFFP and FARS are viewed differently by casual observers, which has implications for patient care and future research. While CFFP showed gaze alterations (compared with Control) in both rest and facial expression states, FARS caused gaze alterations only with facial movement.
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
Armstrong, Andrew J. , Liu, Vinnie Y.T. , Selvaraju, Ramprasaath R., Chen, Emmalyn , Simko, Jeffry, DeVries, Sandy, Sartor, Oliver , Sandler, Howard M. , Mohamad, Osama , Huang, Huei–Chung, Griffin, Jacqueline , Esteva, Andre , Carson, John H., Peters, Christopher A., Gore, Elizabeth , Monson, Jedidiah M., Augspurger, Mark E., El‐Gayed, Ali , Rodgers, Joseph P., McKay, Rana R. , Morgan, Todd M. , Feng, Felix Y. , Nguyen, Paul L. , Tran, Phuoc T , Spratt, Daniel E , Lee, Steve P , El-Gayed, Ali , McKay, Rana R , Morgan, Todd M , Feng, Felix Y , Sartor, A Oliver , Sandler, Howard M , Armstrong, Andrew J , Yamashita, Rikiya , Spratt, Daniel E. , Carson, John Hi

Mayo Clinic

Journal of Clinical Oncology | April 16, 2025 | Volume: 43 | Issue: 32 | Pages: 3494-3504

10.1200/jco.24.00365 | PMID 40239134 Get It

PURPOSE Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are needed to guide ADT duration. METHODS A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data (age, prostate-specific antigen, Gleason, and T stage) from six NRG Oncology phase III randomized radiotherapy trials. The novel MMAI-derived biomarker was developed to predict the differential benefit of LT-ADT on the primary end point, distant metastasis (DM). MMAI predictive utility was validated on a seventh randomized trial, RTOG 9202 (N = 1,192), which randomly assigned men to RT + ST-ADT (4 months) versus RT + LT-ADT (28 months). Fine-Gray and cumulative incidence analyses for DM, and secondarily, death with DM, were performed. Deaths without DM were treated as competing risks. RESULTS In the validation cohort (median follow-up, 17.2 years), LT-ADT significantly improved DM from 26% to 17% (subdistribution hazard ratio [sHR], 0.64 [95% CI, 0.50 to 0.82], P < .001). A significant biomarker-treatment predictive interaction was observed ( P = .04) for DM, whereby MMAI biomarker–positive men (n = 785, 66%) had reduced DM with LT-ADT versus ST-ADT (sHR, 0.55 [95% CI, 0.41 to 0.73], P < .001), whereas no treatment benefit was observed for MMAI biomarker–negative men (n = 407; sHR, 1.06 [95% CI, 0.61 to 1.84], P = .84). The estimated 15-year DM risk difference between RT + LT-ADT and RT + ST-ADT was 14% in MMAI biomarker–positive men and 0% in MMAI biomarker–negative men. The MMAI biomarker was also prognostic for DM, irrespective of treatment (sHR, 2.35 [95% CI, 1.72 to 3.19], P < .001). CONCLUSION To our knowledge, the MMAI model is the first validated predictive biomarker to guide ADT duration with RT in localized/locally advanced PCa. Approximately one third of men with high-risk PCa could safely be spared the additional 24 months of ADT and the associated morbidity.
Amyloid precursor protein and presenilin‐1 knock‐in immunodeficient mice exhibit intraneuronal Aβ pathology, microgliosis, and extensive neuronal loss
Yeapuri, Pravin, Foster, Emma G. , Kadry, Rana, Bhattarai, Shaurav , Lu, Yaman, Sil, Susmita , Sapkota, Roshan , Srivastava, Shefali , Kumar, Mohit , Mosley, R. Lee , Machhi, Jatin , Ikezu, Tsuneya , Poluektova, Larisa Y. , Gendelman, Howard Eliot

Mayo Clinic

Alzheimer's & Dementia | April 8, 2025 | Volume: 21 | Issue: 4 | Pages: No page available

10.1002/alz.70084 | PMID 40195277 Get It

AbstractINTRODUCTIONTransgenic mice overexpressing familial Alzheimer's disease (AD) mutations (FAD) show non‐physiological traits, and their immunocompetent backgrounds limit their use in AD immunotherapy research. Preclinical models that reflect human immune responses in AD are needed.METHODSUsing CRISPR‐Cas9, we developed single (NA) and double (NAPS) knock‐in (KI) amyloid precursor protein (APP)KM670,671NL (Swedish) and presenilin 1 (PS 1)M146VFAD mutations on an immunodeficient NOG (NOD.Cg‐PrkdcscidIl2rgtm1Sug/JicTac) background. The models were confirmed by Sanger sequencing and evaluated for AD‐like pathology.RESULTSBoth NA and NAPS mice developed pathology without overexpression artifacts. Mutation‐induced upregulation of APP‐CTF‐β led to intraneuronal human amyloid beta (Aβ) (6E10) deposits and amyloid‐associated microgliosis as early as 3 months, which increased with age. The addition of the PS 1M146V mutation doubled the amyloid load. The models displayed broad neuronal loss, resulting in brain atrophy in older mice.DISCUSSIONThese models replicate intraneuronal amyloid pathology and, with human immune reconstitution potential, enable novel studies of human immune responses in AD.Highlights A novel Alzheimer's disease (AD) knock‐in (KI) mouse was developed and characterized on an immunodeficient NOG background. The model provides a platform for human immune studies and the evaluation of immunotherapies for AD. The KI mice demonstrate intraneuronal Aβ deposits and amyloid‐associated microglial reactions. KI mice demonstrate extensive neuronal loss. Human immune reconstitution enables studies of infectious AD co‐morbidities, such as the human immunodeficiency and herpes simplex viruses.
Spanish Language Adaptation of the ALLFTD Genetic Counseling Protocol in Costa Rica (P3-3.019)
Godoy, Maria Eugenia , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley, Salas, Jorge Mario Leon, Josephy‐Hernandez, Sylvia , Ibáñez, Agustín

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211965 Get It

The road towards implementation of TMEM106B genetic testing in clinical practice in progranulin pathogenic variant carriers (P3-3.020)
Ramos, Eliana Marisa , Geschwind, Daniel, Mirza, Saira Saeed , Masellis, Mario, Rogaeva, Ekaterina, Chisman‐Russell, Lucy, Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam, Rosen, Howard, Boeve, Bradley, Rademakers, Rosa , Vandebergh, Marijne , Rohrer, Jonathan D.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210476 Get It